Middle East & Africa Mid-Size Pharmaceutical Market Forecast to 2028 – COVID

Middle East & Africa Mid-Size Pharmaceutical Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Prescription and Over-the-Counter), Drug Development Type (In-House and Outsource), Formulation (Tablets and Capsules, Injectables, Sprays, and Other Formulations), and Therapy Class (Cardiovascular Diseases, Pain Management, Diabetes, Cancer, and Other Conditions)

Report Code : BMIRE00026184 | Region : LAMEA | Industry : Pharmaceuticals | Published Date : 23/Sep/2022

The mid-size pharmaceutical market in the Middle East & Africa is expected to grow from US$ 19,569.41 million in 2022 to US$ 23,913.96 million by 2028; it is estimated to grow at a CAGR of 3.4% from 2022 to 2028.

Pharmaceutical companies are interested in ensuring R&D achieves their intended goal. The number of new drugs approved each year has also increased over the last decade. Efforts are being made to achieve greater effectiveness and efficiency in meeting patients' needs. Recent studies have estimated average R&D costs per new drug are less than US$ 1 billion to over US$ 2 billion per drug. These estimates include the cost of laboratory and clinical trials of successful new drugs and drugs that enter clinical trials but fail or do not go through the laboratory development phase. These top trends transform the pharmaceutical industry and can have short-term and long-term implications. Therefore, the surging focus on R&D drives the growth of the Middle East & Africa mid-size pharmaceutical market.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Middle East & Africa mid-size pharmaceutical market. The Middle East & Africa mid-size pharmaceutical market is expected to grow at a good CAGR during the forecast period.

Middle East & Africa Mid-Size Pharmaceutical Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Mid-Size Pharmaceutical Market Segmentation

The Middle East & Africa mid-size pharmaceutical market is segmented on the basis of type, drug development type, formulation, therapy class, and country.

Based on type, the Middle East & Africa mid-size pharmaceutical market is bifurcated into prescription and over-the-counter. In 2022, the over-the-counter segment accounted for a larger market share. Based on drug development type, the market is bifurcated into in-house and outsource. The outsource segment held a larger market share in 2022. Based on formulation, the Middle east & Africa mid-size pharmaceutical market is segmented into tablets and capsules, injectables, sprays, and other formulations. The tablets & capsules segment held the largest market share in 2022. Based on therapy class, the market is segmented into cardiovascular diseases, pain management, diabetes, cancer, and other conditions. The diabetes segment held the largest market share in 2022. Based on country, the Middle East & Africa mid-size pharmaceutical market is segmented into Saudi Arabia, South Africa, the UAE, and Rest of Middle East & Africa. Saudi Arabia held the largest market share in 2022.

Alexion Pharmaceuticals, Inc.; Bausch Health Companies Inc.; Daiichi Sankyo Company Limited; Endo Pharmaceuticals Inc.; Mallinckrodt; and Sun Pharmaceutical Industries Ltd are among the leading companies operating in the mid-size pharmaceutical market in the region.

At 3.4% CAGR, the Middle East & Africa Mid-Size Pharmaceutical Market market is speculated to be worth US$ 23,913.96 Million by 2028, says The Insight Partners

According to The Insight Partners’ research, the Middle East & Africa mid-size pharmaceutical market market was valued at US$ 19,569.41 million in 2022 and is expected to reach US$ 23,913.96 million by 2028, registering an annual growth rate of 3.4% from 2022 to 2028. Rising number of healthcare start-ups and increasing focus on R&D market are the critical factors attributed to the market expansion.

Over the last decade, the pharmaceutical industry has witnessed many transformational trends and innovations that will rapidly improve the medicines available to patients around the world. In just ten years, the influence of artificial intelligence and big data on diagnosing and treating disease and a shift toward preventing life-threatening conditions rather than medicating them lead to evolution of healthcare. With the evolution of recent technologies, new entrants initiate several health start-ups, thereby influencing the mid-size pharmaceutical market. For Instance: Alpha zyme was founded in 2018 by Christopher Benoit, an expert in enzyme development and production. In October 2020, Alp zyme partnered with Qualio to facilitate the company’s growth.

Unlike large pharmaceutical companies, medium-sized pharmaceutical companies are usually not constrained by huge overheads and bureaucracy. However, these companies have a narrow business focus and can focus on specific areas of drug development. This allows them to focus primarily on illnesses too small for larger competitors to attack. Additionally, healthcare systems rapidly transform healthcare models with online access and tools for patient involvement, remote monitoring, and other virtual care modalities. In recent years, partnerships between the pharmaceutical industry and digital health companies have increased significantly. These commercial deployment deals are aimed at digitally-enabled pharmaceutical products, creating new companies, or multibillion-dollar acquisitions. Thus, pharma companies are a growing part of the digital health boom providing a significant growth opportunity for the mid-size pharmaceutical market in the coming years.

On the contrary, high competition among market players hurdles the growth of Middle East & Africa mid-size pharmaceutical market market.

Based on type, the Middle East & Africa mid-size pharmaceutical market is bifurcated into prescription and over-the-counter. The over-the-counter segment holds 63.7% market share in 2022, amassing US$ 12,353.67 million. It is projected to garner US$ 15,350.31 million by 2028 to expand at 3.7% CAGR during 2022–2028.

Based on drug development type, the Middle East & Africa mid-size pharmaceutical market is bifurcated into in-house and outsource. The outsource segment holds 90.2% market share in 2022, amassing US$ 17,594.38 million. It is projected to garner US$ 21,919.70 million by 2028 to expand at 3.7% CAGR during 2022–2028.

Based on formulation, the Middle East & Africa mid-size pharmaceutical market is segmented into tablets and capsules, injectables, sprays, and other formulations. With 36.3% share of the domain, the tablets and capsules segment dominates the market in 2022. It accrued US$ 7,049.36 million in 2022 and is estimated to generate US$ 8,956.98 million by 2028 to grow at a CAGR of 4.1% over the forecast period.

By therapy class, the Middle East & Africa mid-size pharmaceutical market is segmented into cardiovascular diseases, pain management, diabetes, cancer, and other conditions. With 34.3% share of the domain, the diabetes segment dominates the market in 2022. It accrued US$ 6,703.19 million in 2022 and is estimated to generate US$ 8,291.29 million by 2028 to grow at a CAGR of 3.6% over the forecast period.

Our regional analysis states that Saudi Arabia captured 39.5% market share in 2022. It is assessed at US$ 7,731.32 million in 2022 and is likely to hit US$ 9,744.94 million by 2028, exhibiting a CAGR of 3.9% during the forecast period.

Key players dominating the Middle East & Africa mid-size pharmaceutical market market are Alexion Pharmaceuticals, Inc.; Bausch Health Companies Inc.; Daiichi Sankyo Company Limited; Endo Pharmaceuticals Inc.; Mallinckrodt; and Sun Pharmaceutical Industries Ltd among others.

A few major key developments among the top market players are described below:

In April 2022, Regeneron Pharmaceuticals, Inc. and Checkmate Pharmaceuticals, Inc. announced a definitive agreement for Regeneron to acquire Checkmate for $10.50 per share of Checkmate common stock in an all-cash transaction. Checkmate's entire stock value is estimated to be around $250 million in the proposed acquisition. Contact Us

Contact Person: Sameer Joshi

Phone: +1- 646- 491- 9876

Email id: [email protected]

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 MEA Mid-Size Pharmaceutical – By Type

1.3.2 MEA Mid-Size Pharmaceutical – By Drug Development Type

1.3.3 MEA Mid-Size Pharmaceutical – By Formulation

1.3.4 MEA Mid-Size Pharmaceutical – By Therapy Area

1.3.5 MEA Mid-Size Pharmaceutical – By Country

2. Mid-Size Pharmaceutical– Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. MEA Mid-Size Pharmaceutical – Market Landscape

4.1 Overview

4.2 MEA PEST Analysis

4.3 Expert Opinion

5. Mid-Size Pharmaceutical Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Rising Cases of Chronic Disorders

5.1.2 New Product Approval and Launches

5.2 Market Restraints

5.2.1 High Competition Among Market Players

5.3 Market Opportunities

5.3.1 Rising Number of Healthcare Start-ups

5.4 Future Trends

5.4.1 Surging Focus on R&D

5.5 Impact Analysis

6. Mid-Size Pharmaceutical Market– MEA Analysis

6.1 MEA Mid-Size Pharmaceutical Market Revenue Forecast And Analysis

7. MEA Mid-Size Pharmaceutical Market Revenue and Forecasts To 2028– by Type

7.1 Overview

7.2 MEA Mid-Size Pharmaceutical Market Revenue Share, by Type (2022 and 2028)

7.3 Prescription

7.3.1 Overview

7.3.2 Prescription: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

7.4 Over-the-Counter (OTC)

7.4.1 Overview

7.4.2 Over-the-Counter: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

8. MEA Mid-Size Pharmaceutical Market Analysis – By Drug Development Type

8.1 Overview

8.2 MEA Mid-Size Pharmaceutical Market Revenue Share, by Drug Development Type (2022 and 2028)

8.3 In-House

8.3.1 Overview

8.3.2 In-House: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Outsource

8.4.1 Overview

8.4.2 Outsource: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

9. MEA Mid-Size Pharmaceutical Market – By Formulation

9.1 Overview

9.2 MEA Mid-Size Pharmaceutical Market, by Formulation, 2022 and 2028 (%)

9.3 Tablets and Capsules

9.3.1 Overview

9.3.2 Tablets and Capsules: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

9.4 Injectables

9.4.1 Overview

9.4.2 Injectables: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

9.5 Sprays

9.5.1 Overview

9.5.2 Sprays: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

9.6 Other Formulations

9.6.1 Overview

9.6.2 Others: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

10. MEA Mid-Size Pharmaceutical Market – By Therapy Class

10.1 Overview

10.2 MEA Mid-Size Pharmaceutical Market, by Therapy Class, 2022 and 2028 (%)

10.3 Cardiovascular Diseases

10.3.1 Overview

10.3.2 Cardiovascular Diseases: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

10.4 Pain Management

10.4.1 Overview

10.4.2 Pain Management: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

10.5 Diabetes

10.5.1 Overview

10.5.2 Diabetes: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

10.6 Cancer

10.6.1 Overview

10.6.2 Cancer: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

10.7 Other Diseases

10.7.1 Overview

10.7.2 Other Diseases: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

11. MEA Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 – Country Analysis

11.1 Overview

11.1.1 MEA Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Country (%)

11.1.1.1 UAE: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)

11.1.1.1.1 Overview

11.1.1.1.2 UAE: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)

11.1.1.1.3 UAE: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Type (US$ Million)

11.1.1.1.4 UAE: Mid-Size Pharmaceutical Market Revenue and Forecasts To 2028, By Drug Development Type (US$ Million)

11.1.1.1.5 UAE: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)

11.1.1.1.6 UAE: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)

11.1.1.2 Saudi Arabia: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)

11.1.1.2.1 Overview

11.1.1.2.2 Saudi Arabia: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)

11.1.1.2.3 Saudi Arabia: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Type (US$ Million)

11.1.1.2.4 Saudi Arabia: Mid-Size Pharmaceutical Market Revenue and Forecasts To 2028, By Drug Development Type (US$ Million)

11.1.1.2.5 Saudi Arabia: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)

11.1.1.2.6 Saudi Arabia: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)

11.1.1.3 South Africa: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)

11.1.1.3.1 Overview

11.1.1.3.2 South Africa Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)

11.1.1.3.3 South Africa: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Type (US$ Million)

11.1.1.3.4 South Africa: Metabolomics Market Revenue and Forecasts To 2028, By Drug Development Type (US$ Million)

11.1.1.3.5 South Africa: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)

11.1.1.3.6 South Africa: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)

11.1.1.4 Rest of MEA: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)

11.1.1.4.1 Overview

11.1.1.4.2 Rest of MEA: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)

11.1.1.4.3 Rest of MEA: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Type (US$ Million)

11.1.1.4.4 Rest of MEA: Metabolomics Market Revenue and Forecasts To 2028, By Drug Development Type (US$ Million)

11.1.1.4.5 Rest of MEA: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)

11.1.1.4.6 Rest of MEA: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)

12. Mid-Size Pharmaceutical Market–Industry Landscape

12.1 Overview

12.2 Growth Strategies Done by the Companies in the Market, (%)

12.3 Organic Developments

12.3.1 Overview

12.4 Inorganic Developments

12.4.1 Overview

13. Company Profiles

13.1 DAIICHI SANKYO COMPANY LIMITED

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Bausch Health Companies Inc.

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 Sun Pharmaceutical Industries Ltd

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 Alexion Pharmaceuticals, Inc.

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 Mallinckrodt

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 Endo Pharmaceuticals Inc.

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms

LIST OF TABLES.

Table 1.             UAE: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Type (US$ Million)

Table 2.             UAE: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Drug Development Type (US$ Million)

Table 3.             UAE: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)

Table 4.             UAE: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)

Table 5.             Saudi Arabia: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Type (US$ Million)

Table 6.             Saudi Arabia: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Drug Development Type (US$ Million)

Table 7.             Saudi Arabia: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)

Table 8.             Saudi Arabia: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)

Table 9.             South Africa Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Type (US$ Million)

Table 10.          South Africa: Metabolomics Market Revenue and Forecasts to 2028, By Drug Development Type (US$ Million)

Table 11.          South Africa: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)

Table 12.          South Africa: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)

Table 13.          Rest of MEA: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Type (US$ Million)

Table 14.          Rest of MEA: Metabolomics Market Revenue and Forecasts to 2028, By Drug Development Type (US$ Million)

Table 15.          Rest of MEA: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)

Table 16.          Rest of MEA: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)

Table 17.          Organic Developments Done By Companies

Table 18.          Inorganic Developments Done By Companies

Table 19.          Glossary of Terms

LIST OF FIGURES.

Figure 1.           MEA Mid-Size Pharmaceutical Segmentation

Figure 2.           MEA Mid-Size Pharmaceutical Segmentation, By Country

Figure 3.           MEA Mid-Size Pharmaceutical Overview

Figure 4.           Over-the-Counter Segment Held Largest Share by Type in MEA Mid-Size Pharmaceutical Market

Figure 5.           Saudi Arabia is Expected to Show Remarkable Growth During the Forecast Period

Figure 6.           Middle East & Africa: PEST Analysis

Figure 7.           MEA Mid-Size Pharmaceutical Market– Revenue Forecast And Analysis – 2020- 2028

Figure 8.           MEA Mid-Size Pharmaceutical Market Revenue Share, by Type (2022 and 2028)

Figure 9.           MEA Prescription: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 10.        MEA Over-the-Counter: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 11.        MEA Mid-Size Pharmaceutical Market Revenue Share, by Drug Development Type (2022 and 2028)

Figure 12.        MEA In-House: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 13.        MEA Outsource: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 14.        MEA Mid-Size Pharmaceutical Market, by Formulation, 2022 and 2028 (%)

Figure 15.        MEA Tablets and Capsules: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 16.        MEA Injectables: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 17.        MEA Sprays: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 18.        MEA Others: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 19.        MEA Mid-Size Pharmaceutical Market, by Therapy Class, 2022 and 2028 (%)

Figure 20.        MEA Cardiovascular Diseases: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 21.        MEA Pain Management: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 22.        MEA Diabetes: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 23.        MEA Cancer: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 24.        MEA Other Diseases: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 25.        MEA Mid-Size Pharmaceutical Market Revenue Overview, by Country, 2021 (US$ Million)

Figure 26.        MEA Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028, By Country (%)

Figure 27.        UAE: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)

Figure 28.        Saudi Arabia: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)

Figure 29.        South Africa: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)

Figure 30.        Rest of MEA: Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 (US$ Million)

Figure 31.        Growth Strategies Done by the Companies in the Market, (%)

The List of Companies - Middle East & Africa Mid-Size Pharmaceutical Market

● Alexion Pharmaceuticals, Inc.

● Bausch Health Companies Inc.

● Daiichi Sankyo Company Limited

● Endo Pharmaceuticals Inc.

● Mallinckrodt

● ssSun Pharmaceutical Industries Ltd

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Middle East & Africa mid-size pharmaceutical market

● Highlights key business priorities in order to assist companies to realign their business strategies

● The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa mid-size pharmaceutical market, thereby allowing players across the value chain to develop effective long-term strategies

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets

● Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the mid-size pharmaceutical market, as well as those hindering it

● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

TOP